These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34891223)

  • 1. Betibeglogene Autotemcel Gene Therapy for Non-β
    Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
    N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
    Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
    N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
    Locatelli F; Lang P; Wall D; Meisel R; Corbacioglu S; Li AM; de la Fuente J; Shah AJ; Carpenter B; Kwiatkowski JL; Mapara M; Liem RI; Cappellini MD; Algeri M; Kattamis A; Sheth S; Grupp S; Handgretinger R; Kohli P; Shi D; Ross L; Bobruff Y; Simard C; Zhang L; Morrow PK; Hobbs WE; Frangoul H;
    N Engl J Med; 2024 May; 390(18):1663-1676. PubMed ID: 38657265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
    Kanter J; Walters MC; Krishnamurti L; Mapara MY; Kwiatkowski JL; Rifkin-Zenenberg S; Aygun B; Kasow KA; Pierciey FJ; Bonner M; Miller A; Zhang X; Lynch J; Kim D; Ribeil JA; Asmal M; Goyal S; Thompson AA; Tisdale JF
    N Engl J Med; 2022 Feb; 386(7):617-628. PubMed ID: 34898139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
    Sii-Felice K; Giorgi M; Leboulch P; Payen E
    Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia.
    Hongeng S; Anurathapan U; Songdej D; Phuphuakrat A; Jongrak K; Parsons G; Deary B; Bonner M; Veres G; Asmal M
    Blood Adv; 2021 Jul; 5(13):2701-2706. PubMed ID: 34196676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug product attributes predict clinical efficacy in betibeglogene autotemcel gene therapy for β-thalassemia.
    Whitney D; Shestopalov I; Fincker M; d'Anjou M; Kral K; Gayron M; Pierciey FJ; Colvin RA
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101155. PubMed ID: 38074412
    [No Abstract]   [Full Text] [Related]  

  • 8. Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.
    Kansal AR; Reifsnider OS; Brand SB; Hawkins N; Coughlan A; Li S; Cragin L; Paramore C; Dietz AC; Caro JJ
    J Mark Access Health Policy; 2021 Jun; 9(1):1922028. PubMed ID: 34178295
    [No Abstract]   [Full Text] [Related]  

  • 9. Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients.
    Ouyang W; Dong G; Zhao W; Li J; Zhou Z; Yang G; Liu R; Li Y; Zhang Q; Du X; Sun H; Gu Y; Lai Y; Liu S; Liu C
    Hum Gene Ther; 2021 May; 32(9-10):481-494. PubMed ID: 33256481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
    Kanter J; Thompson AA; Pierciey FJ; Hsieh M; Uchida N; Leboulch P; Schmidt M; Bonner M; Guo R; Miller A; Ribeil JA; Davidson D; Asmal M; Walters MC; Tisdale JF
    Am J Hematol; 2023 Jan; 98(1):11-22. PubMed ID: 36161320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.
    Boulad F; Maggio A; Wang X; Moi P; Acuto S; Kogel F; Takpradit C; Prockop S; Mansilla-Soto J; Cabriolu A; Odak A; Qu J; Thummar K; Du F; Shen L; Raso S; Barone R; Di Maggio R; Pitrolo L; Giambona A; Mingoia M; Everett JK; Hokama P; Roche AM; Cantu VA; Adhikari H; Reddy S; Bouhassira E; Mohandas N; Bushman FD; Rivière I; Sadelain M
    Nat Med; 2022 Jan; 28(1):63-70. PubMed ID: 34980909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
    Langer AL; Esrick EB
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy in transfusion-dependent non-β0/β0 genotype β-thalassemia: first real-world experience of beti-cel.
    Mirza A; Ritsert ML; Tao G; Thakar H; Lobitz S; Heine S; Koscher L; Dürken M; Schmitt A; Schmitt M; Pavel P; Laier S; Jakoby D; Greil J; Kunz J; Kulozik A
    Blood Adv; 2025 Jan; 9(1):29-38. PubMed ID: 39418614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exagamglogene Autotemcel for Severe Sickle Cell Disease.
    Frangoul H; Locatelli F; Sharma A; Bhatia M; Mapara M; Molinari L; Wall D; Liem RI; Telfer P; Shah AJ; Cavazzana M; Corbacioglu S; Rondelli D; Meisel R; Dedeken L; Lobitz S; de Montalembert M; Steinberg MH; Walters MC; Eckrich MJ; Imren S; Bower L; Simard C; Zhou W; Xuan F; Morrow PK; Hobbs WE; Grupp SA;
    N Engl J Med; 2024 May; 390(18):1649-1662. PubMed ID: 38661449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
    Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
    PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coordinated β-globin expression and α2-globin reduction in a multiplex lentiviral gene therapy vector for β-thalassemia.
    Nualkaew T; Sii-Felice K; Giorgi M; McColl B; Gouzil J; Glaser A; Voon HPJ; Tee HY; Grigoriadis G; Svasti S; Fucharoen S; Hongeng S; Leboulch P; Payen E; Vadolas J
    Mol Ther; 2021 Sep; 29(9):2841-2853. PubMed ID: 33940155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.
    Magrin E; Semeraro M; Hebert N; Joseph L; Magnani A; Chalumeau A; Gabrion A; Roudaut C; Marouene J; Lefrere F; Diana JS; Denis A; Neven B; Funck-Brentano I; Negre O; Renolleau S; Brousse V; Kiger L; Touzot F; Poirot C; Bourget P; El Nemer W; Blanche S; Tréluyer JM; Asmal M; Walls C; Beuzard Y; Schmidt M; Hacein-Bey-Abina S; Asnafi V; Guichard I; Poirée M; Monpoux F; Touraine P; Brouzes C; de Montalembert M; Payen E; Six E; Ribeil JA; Miccio A; Bartolucci P; Leboulch P; Cavazzana M
    Nat Med; 2022 Jan; 28(1):81-88. PubMed ID: 35075288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified lentiviral globin gene therapy for pediatric β
    Li S; Ling S; Wang D; Wang X; Hao F; Yin L; Yuan Z; Liu L; Zhang L; Li Y; Chen Y; Luo L; Dai Y; Zhang L; Chen L; Deng D; Tang W; Zhang S; Wang S; Cai Y
    Cell Stem Cell; 2024 Jul; 31(7):961-973.e8. PubMed ID: 38759653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies.
    Taher AT; Bou-Fakhredin R; Kattamis A; Viprakasit V; Cappellini MD
    Expert Rev Hematol; 2021 Oct; 14(10):897-909. PubMed ID: 34493145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Droplet digital polymerase chain reaction-based quantitation of therapeutic lentiviral vector copies in transduced hematopoietic stem cells.
    Phuphanitcharoenkun S; Bhukhai K; Phanthong P; Prasongtanakij S; Linn AK; Sutjarit N; Anurathapan U; Leboulch P; Payen E; Hongeng S; Borwornpinyo S
    Cytotherapy; 2024 Jun; 26(6):586-591. PubMed ID: 38551525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.